Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Clonidine-Induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain
This study has been completed.
Sponsors and Collaborators: Wake Forest University
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by: National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier: NCT00350532
  Purpose

The purpose of this study is to compare the amount of acetylcholine release after a single injection of clonidine in normal volunteers and individuals with neuropathic pain.


Condition Intervention Phase
Pain
Drug: clonidine
Phase II

Drug Information available for: Clonidine Acetylcholine Acetylcholine chloride Clonidine hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Placebo Control, Single Group Assignment, Efficacy Study
Official Title: Clonidine-Induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain

Further study details as provided by National Institute of Neurological Disorders and Stroke (NINDS):

Primary Outcome Measures:
  • Acetylcholine concentration in cerebrospinal fluid [ Time Frame: at 60 minutes after injection of clonidine ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 48
Study Start Date: September 2004
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
Drug: clonidine
Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)

Detailed Description:

This study is part of a pain center grant that focuses on how pain, especially chronic neuropathic pain, alters the response to traditional and non-traditional analgesics (pain medications).

The way that nerve fibers carry pain information to the brain is thought to change after surgery and in cases of chronic pain. For this reason, some medicines work better to relieve pain in healthy people who have a sudden painful injury when compared to people after surgery or to people with chronic pain. Currently available pain medications may not relieve all types of pain or may relieve pain only at doses that produce side effects and potential complications.

The aim of this study is to understand the mechanisms by which intrathecal clonidine (or clonidine injected into cerebrospinal fluid) increases in potency and efficacy by examining the cerebrospinal fluid of healthy individuals, before and after clonidine administration, as well as looking at the spinal fluid of people with chronic neuropathic nerve pain. More specifically, in this study, researchers will compare acetylcholine release (a protein-like substance found in cerebrospinal fluid) in normal volunteers and patients with neuropathic pain after a single injection of clonidine.

After baseline measurements, including blood pressure and heart rate, participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.

Duration of the study for participants is 1 day, and includes 1 visit to the research center, lasting approximately 3 hours.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult volunteers
  • Patients with neuropathic pain

Exclusion Criteria:

  • Pregnancy
  • Allergy to clonidine
  • Currently taking clonidine or other direct a2-adrenergic agonists
  • Taking cholinesterase inhibitors
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00350532

Locations
United States, North Carolina
Wake Forest University School of Medicine, Medical Center Boulevard
Winston-Salem, North Carolina, United States, 27157-1009
The Center for Clinical Research, 145 Kimel Park Drive
Winston-Salem, North Carolina, United States, 27103
Sponsors and Collaborators
Wake Forest University
Investigators
Principal Investigator: James C. Eisenach, M.D. Wake Forest University
Principal Investigator: Richard Rauck, M.D. The Center for Clinical Research
  More Information

Responsible Party: Wake Forest University School of Medicine ( James C. Eisenach, MD, Professor of Anesthesiology )
Study ID Numbers: P01NS041386_TRIAL2
Study First Received: July 5, 2006
Last Updated: July 11, 2008
ClinicalTrials.gov Identifier: NCT00350532  
Health Authority: United States: Food and Drug Administration

Keywords provided by National Institute of Neurological Disorders and Stroke (NINDS):
pain, chronic pain
acetylcholine
clonidine
a2-adrenergic agonists
alpha2-adrenergic agonists

Study placed in the following topic categories:
Clonidine
Acetylcholine
Pain

Additional relevant MeSH terms:
Sympatholytics
Neurotransmitter Agents
Vasodilator Agents
Adrenergic alpha-Agonists
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Physiological Effects of Drugs
Cardiovascular Agents
Antihypertensive Agents
Cholinergic Agents
Pharmacologic Actions
Adrenergic Agonists
Autonomic Agents
Sensory System Agents
Therapeutic Uses
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 14, 2009